Encouragingly, a phase I clinical trial investigating anti-CSPG4 radioimmunotherapy with a mAb (9.2.27) conjugated to an α-particle-emitting radioisotope which was administered systemically in patients with melanoma reported no adverse events while some clinical benefits were observed (108). Here, CSPG4 is linked to melanoma.